Pharmacological profile and therapeutic perspectives of semotiadil fumarate (SD-3211), a novel benzothiazine Ca2+ antagonist

Cardiovascular Drug Reviews

Volumn 14, Issue 2, 1996, Pages 97-134

  Nakayama, Koichi ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Antianginal; Antiarrhythmic; Antihypertensive; Benzothiazine; Ca2+ antagonist; Ca2+ channel; Semotiadil

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; RENTIAPRIL; SESAMODIL FUMARATE; VERAPAMIL;

ANGINA PECTORIS; ARTICLE; BRAIN ARTERY; CARDIOSELECTIVITY; CARDIOVASCULAR DISEASE; DRUG ABSORPTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; EDEMA; HEADACHE; HEART ARRHYTHMIA; HEART ATRIOVENTRICULAR NODE; HEART PALPITATION; HEART PAPILLARY MUSCLE; HUMAN; HYPERTENSION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE ACTION POTENTIAL; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; VASOCONSTRICTION;

EID: 0029809864     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1996.tb00222.x     Document Type: Article

References (80)

1. Aotsuka T, Hosono H, Kurihara T, Nakamura Y, Matsui T, Kobayashi F. 1,4-Benzothiazine-2-acetic acid derivatives, processes for production thereof and their use. Eur. Pat. 492,667 A, 1992 [C.A. 117: 151,006, 1992].
2. Bigger JT. Symposium on flecainide acetate. Am J Cardiol 1984;53:1B-122B
3. Burges RA, Dodd MG, Gardiner DG. Pharmacological profile of amlodipine. Am J Cardiol 1989;64:191-211
4. Cavalla JF, Johnson JM. Benzothiazine derivatives with pharmaceutical properties Brit. Pat. 1,244,481, 1971 [C.A. 75: 129,824, 1971].
5. Fleckenstein A. Discovery and mechanism of action of specific calcium-antagonistic inhibitors of excitation-contraction coupling in the mammalian myocardium. In Fleckenstein A, ed. Calcium antagonism in heart and smooth muscle. Experimental facts and therapeutic prospects. New York: John Wiley, 1988: 34-108
6. 2+ antagonist having a benzothiazine skeleton. Chem Pharm Bull 1992;40:2901-2904
7. 2+ antagonist having a benzothiazine skeleton, and structure-activity relationships. Bioorg Med Chem 1994,2 235-242.
8. 2+ antagonistic activity of 2-[2-[(aminoalkyl)oxy]-5-methoxyphenyl]-3,4-dihydro-4-methyl-3-oxo-2H-1,4- benzothiazines. J Med Chem 1990;33:1898-1905.
9. Fujita M, Ota A, Ito S, Yamamoto K, Kawashima Y A novel, convenient synthesis of 2-aryl-3-oxo-3,4-dihydro-2H-1,4-benzothiazines. Synthesis 1988.599-604.
10. Fujita M, Ota A, Ito S, et al Synthesis and calcium antagonistic activity of (+)-(R)- and (-)-(S)-3-acetyl-2-[5-methoxy-2-[4-[N-methyl-N-(3,4,5-trimethoxy-phenethyl) amino]butoxy]phenyl]benzothiazoline hydrochloride. Chem Pharm Bull 1990;38:936-941.
11. Fujita M, Ito S, Suhara H, Ibuki H, Kawashima Y. Synthesis and calcium antagonistic activities of fecal metabolites of a new calcium antagonist (+)-(R)-3,4-dihydro-2-[5-methoxy-2-[3-[N-methyl-N-[2-[3,4-methylenedioxy) phenoxy]ethyl]amino]propoxy]phenyl]-4-methyl-3oxo-2H-1,4-benzothiazine (SD-3211) in rats. Yakugaku Zasshi 1991;111:59-64.
12. Fukuchi M, Uematsu T, Nagashima S, Nakashima M. Antiarrhythmic effects of a benzothiazine derivative (SD-3211) and its stereoisomer (SA3212) in anesthetized rats and isolated perfused rat hearts compared with bepridil. Naunyn Schmied Arch Pharmacol 1990;341:557-564.
13. Godfraind T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol Rev 1986; 38:321-416.
14. 3H]HOE 166 defines calcium antagonist drug receptor distinct from the 1,4-dihydropyridine binding domain. Naunyn Schmied Arch Pharmacol 1989,340:752-759
15. Hashimoto H, Umemura K, Araki S, et al. Comparison of electrophysiologic and hemodynamic effects of SD-3212, a new antiarrhythmic drug, and flecainide in a canine myocaridal infarction model. Biol Pharm Bull 1994;17:548-550.
16. Henning R, Lerch U, Kaiser J. Benzothiazine derivatives, a drug containing them, and their use Ger. Offen. Pat. 3,347,173 A, 1985 [C.A. 104:88,571, 1986].
17. Himori N, Ono H, Taira N Simultaneous assessment of effects of coronary vasodilators on the coronary blood flow and the myocardial contractility by using the blood-perfused papillary muscle. Jpn J Pharmacol 1976;26:427-435.
18. Hirasawa A, Haruno A, Matsuzaki T, Hashimoto K. Effects of a new antiarrhythmic drug, SD-3212, on canine ventricular arrhythmia models. Jpn Heart J 1992;33:851-861.
19. Hondeghem LM, Katsung BG. Test of a model of antiarrhythmic drug action Effects of quinidine and lidocaine on myocardial conduction. Circulation 1980;61:1217-1224.
20. Hondeghem LM, Katzung BG. Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. Ann Rev Pharmacol Toxicol 1984;24.387-423.
21. Ichihara K, Abiko Y. Effect of diltiazem, a calcium antagonist, on myocardial pH in ischemic canine heart. J Pharmacol Exp Ther 1982;222:720-725.
22. Ichihara K, Sakai K, Abiko Y. Effect of nifedipine and niludipine on myocardial pH in the ischemic canine heart. Arch Intern Pharmacodyn Ther 1986,280:58-73.
23. Ichikawa M, Wanata M, Ohtsuji T, et al Antihypertensive effects of a novel calcium antagonist, semotiadil fumarate (SD-3211), alone and in combination with enalapril or trichlormethiazide in spontaneously hypertensive rats. Biol Pharm Bull 1994;17:1513-1515.
24. 1-receptor stimulation in rabbit coronary artery cells J Physiol 1993;468:379-400.
25. 11C]semotiadil, a benzothiazine calcium antagonist. Appl Radial Isot 1994;45:439-443.
26. Iwao J, Iso T, Oya M. Benzothiazine derivatives for treatment of circulatory disorders. Tokkyo Koho 62-123, 181A, 1987 [C.A. 111. 214,496, 1989].
27. Jasserand D, Francois FH, White R. [(Piperazinyl)alkyl]-2H-1,4-benzothiazin-3-ones or -thiones and [(piperazinyl)atkyl]-2H-1,4-benzoxazinones and -thiones, methods for their preparation and their use as antiallergics, inflammation inhibitors and antiasthmatics. Ger Offen Pat. 4,037,427 A, 1992 [C.A. 117: 90326, 1992].
28. Kageyama M, Nishimura K, Takada T, Miyawaki N, Yamauchi H. SD-3211, a novel benzothiazine calcium antagonist, alone and in combination with a beta-adrenoceptor antagonist, produces antihypertensive effects without affecting heart rate and atrioventricular conduction in conscious renal hypertensive dogs. J Cardiovasc Pharmacol 1991;17:102-107
29. Kageyama M, Yamada H, Satoh K, Taira N. Effects of semotiadil (SD-3211), a benzothiazine calcium antagonist, on blood pressure and atrioventricular conductivity in anesthetized dogs. Jpn J Pharmacol 1992;59:177-182
30. 2+ level and force of contraction in porcine coronary arteries. Brit J Pharmacol 1995;114: 1289-1295.
31. Kawasaki K, Seki K, Hosoda S. Spontaneous rhythmic contractions in isolated human coronary arteries. Experienna 1981;37:1291-1292.
32. Kodama I, Suzuki R, Maruyama K, Toyama J. Electrophysiological effects of SD-3212, a new antiarrhythmic agent with vasodilator action, on guinea pig ventricular cells. Brit J Pharmacol 1995;114:503-509.
33. Krapcho J. Tranquilizing 4-aminoalkyl-2-(2-hydroxy-2-phenylethyl-2H-1,4-benzothiazin-3(4H)-ones. Ger. Offen. Pat. 1,926,129A, 1970 [C.A. 74: 42370, 1971].
34. Krapcho J. Anti-inflammatory agents. U.S. Pat. 348,433, 1976 [CA 84:180,247, 1976].
35. Meguro K, Nishikawa K. 1,4-Benzothiazine derivatives. PCT Int Appl. WO 86/03,200 A, 1986 [C.A. 105: 208,931, 1986].
36. Miyawaki N, Furuta T, Shigei T. Electrophysiologic effects of a novel Ca antagonist, SA2572, in isolated rabbit and guinea pig hearts J Cardiovasc Pharmacol 1988,12.65-71
37. 2+ antagonist, in isolated guinea pig and rabbit hearts J Cardiovasc Pharmacol 1990;16:769-775
38. Miyawaki N, Furuta T, Shigei T, Yamauchi H, Iso T. Cardiovascular characterization of SD-3211, a novel benzothiazine calcium channel blocker, in isolated rabbit hearts. Life Sci 1991;48:1903-1909.
39. 2+ channel blocker, SD-3212: A comparison with its enantiomer (SD-3211) Drug Development Res 1991;22:293-298.
40. 2+ channel blocker, SD-3211, in vitro. Clin Exp Pharmacol Physiol 1991;18:579-585.
41. Miyawaki N, Takada T, Satoh C, Kawazu K, Nakata K. Hemodynamic effect and pharmacokinetics of semotiadil fumarate (SD-3211), a novel Ca channel blocker, in spontaneously hypertensive rats. Jpn Heart J 1994;35:571
42. Mori T, Ishigai Y, Fukuzawa A, Chiba K, Shibano T. Pharmacological profile of semotiadil fumarate, a novel calcium antagonist, in rat experimental angina model. Brit J Pharmacol 1995;116:1668-1672.
43. Morikawa N, Takashina H, Ibuki H, et al Studies on the metabolic fate of semotiadil fumarate (SD-3211) (I): Absorption, distribution, metabolism and excretion after single administration to male rats Xenobiotic Metabolism and Disposition (Yakubutsu Doutat) 1992;7:315-330
44. Morishima K, Tahara R, Horiuchi M. Determination of a new calcium antagonist, semotiadil fumarate (SD-3211), and its metabolite in plasma by liquid chromatography with electrochemical detection. J Chromatogr 1990,527:381-388.
45. 2+ and tension caused by KCl and norepinephrine in isolated rat aortas. J Cardiovasc Pharmacol 1995;25:262-267.
46. 2+ channel blocker, in anesthetized dogs with myocardial infarction in comparison with its stereoisomer (SD-3211) and bepridil. Naunyn Schmied Arch Pharmacol 1992;345:688-695.
47. Nakayama K, Morimoto K, Nozawa Y, Tanaka Y. Calcium antagonistic and binding properties of semotiadil (SD-3211), a benzothiazine derivative, assessed in cerebral and coronary arteries. J Cardiovasc Pharmacol 1992,20:380-391.
48. 2+ channel antagonist binding sites in canine skeletal muscle membranes. J Cardiovasc Pharmacol 1994;23:731-740.
49. 2+ mobilization in vascular smooth muscle. Biol Signals 1993;2:241-252.
50. Nishimura K, Miyawaki N, Yamauchi H, Ito T. Tissue selectivity of the novel calcium antagonist sesamodil fumarate in isolated smooth muscle and cardiac muscles. Arzneim-Forsch/Drug Res 1990;40:244-248.
51. Nishiyama A, Tamaki T, Masumura H, et al Effects of semotiadil fumarate (SD-3211) on renal hemodynamics and function in dogs. Eur J Pharmacol 1992;218:311-317.
52. Nayler WG. Other new calcium antagonists. In: Nayler WG, ed. Second generation of calcium antagonists. Berlin: Springer-Verlag, 1991:21.
53. Nayler WG, Panagiotopoulos S, Elz JS, Sturrock WJ. Fundamental mechanisms of action of calcium antagonists in myocardial ischemia. Am J Cardiol 1987;59:75B-83B.
54. 3H]Amlodipine binding to rat cardiac membranes. J Cardiovasc Pharmacol 1991;17:587-592.
55. 2+ antagonist and related compounds. J Chromatogr 1992;593:37-40.
56. 2+ antagonist. Chem Pharm Bull 1993;41:1681-1685.
57. 2+ antagonist, semotiadil (SD-3211). Chem Pharm Bull 1992,40:833-836.
58. Oya M, Baba T, Kato E, Kawashima Y, Watanabe T. Synthesis and antihypertensive activity of N-(mercaptoacyl)thiazolidinecarboxylic acids. Chem Pharm Bull 1982;30:440-461
59. Ozeki M, Kodato S, Yasuda K, Kudo Y, Maeda K. Preparation of thiazine (or oxazine) derivatives as cerebral protectant and calcium antagonists. Eur. Pat. 441,539 A, 1991 [C.A. 115: 232,264, 1991].
60. 2+ channel blockers. Mol Pharmacol 1988;33:363-369.
61. Rhodes D, Sarmiento JG, Herbette LG Kinetics of binding of membrane-active drugs to receptor sites. Diffusion-limited rates for a membrane bilayer approach of 1,4-dihydropyridine calcium channel antagonists to their active site. Mol Pharmacol 1985;27.612-623.
62. Ross G, Stinson E, Schroeder J, Ginsburg R. Spontaneous phasic activity of isolated human coronary arteries. Cardiovasc Res 1980;14:613-618.
63. 2+ antagonist, in rabbit skeletal muscle membranes. Jpn J Pharmacol (Suppl I) 1995;67:96P.
64. Stark G, Kasper K, Stark U, Miyawaki N, Decrinis M, Tritthart HA. Effects of semotiadil, a novel calcium antagonist, on the electrical activity of Langendorff-perfused guinea pig hearts in comparison with diltiazem, amlodipine and nifedipine. Eur J Pharmacol 1995;286:71-78.
65. 2+ antagonist receptor for the novel benzothiazinone compound HOE 166. Naunyn Schmied Arch Pharmacol 1988,337:331-340.
66. Taira N. Differences in cardiovascular profile among calcium channel-blocking drugs Am J Cardiol 1987;59-24B-29B
67. Taira N. Effects of diltiazem and other calcium-antagonists on cardiac functions and coronary blood flow as assessed in blood-perfused dog-heart preparations. In: Bing RJ, ed. New drug therapy with a calcium antagonist. Diltiazem Hakone Symposium '78. Amsterdam: Excerpta Medica, 1979:91-93.
68. Taira N, Kawada M, Satoh K Cardiac versus coronary vasodilator actions of KB-944, a new calcium antagonist in isolated, blood-perfused heart preparations of dogs. J Cardiovasc Pharmacol 1983,5:349-356.
69. Takahashi N, Ito M, Ishida S, Fujino T, Maruyama T, Saikawa T. Electrophysiological effects of SD-3212, a novel antiarrhythmic agent, on rabbit hearts in vivo and in vitro. J Cardiovasc Pharmacol 1995;25:1006-1011
70. Takada T, Miyawaki N, Nishimura K, et al. Cardiohemodynamic effect of a novel calcium antagonist, SD-3211, in the dog. Arch Int Pharmacodyn Ther 1991;309:75-87.
71. Takada T, Miyawaki N, Kageyama M, et al. Antihypertensive effect of a novel calcium antagonist, SD-3211, in experimental hypertensive rats. J Cardiovasc Pharmacol 1991;18:855-862.
72. 2+ handling mechanisms underlying neuropeptide Y-induced contraction in canine basilar artery. Eur J Pharmacol Mol Sec 1995;289:59-66.
73. Teraji T, Oku T, Shiokawa Y. Benzothiazine derivatives and their use. Eur. Pat. 55,917 A, 1982. [C.A. 97: 198,214, 1982.].
74. Teramoto N. Mechanisms of the inhibitory action of semotiadil fumarate, a novel Ca antagonist, on the voltage-dependent Ca current in smooth muscle cells of the rabbit portal vein. Jpn J Pharmacol 1993;61: 183-195.
75. Uchida Y. Decreasing potassium conductance: a possible mechanism of the phasic coronary spasm. Japan Circ J 1985,49:128-139.
76. Uematsu T, Vozeh S, Ha H-R, Hof RP, Follath F. Coronary ligation-reperfusion arrhythmia models in anesthetized rats and isolated perfused rat hearts: Concentration-effect relationship of lidocaine. J Pharmacol Methods 1986,16:53-61.
77. Yamada K, Kohmura A, Kinoshita A, et al. Neuroprotective effect of SD-3211, a non-dihydropyridine type calcium antagonist, is not mediated by local blood flow changes. J Cereb Blood Flow Metab (Suppl 1) 1993;13:S658.
78. Yamamoto K, Fujita M, Tabashi K, et al. Novel calcium antagonists. Synthesis and structure-activity relationship studies of benzothiazoline derivatives. J Med Chem 1988;31:919-930.
79. Yanagisawa H, Fujimoto K, Shimoji Y, Kanezaki T, Iwata N, Kubo Y. Preparation of (morpholinylmethyl) quinolinones and -benzothiazininones for enhancing cerebral circulation. Jpn. Kokai Tokkyo Koho 4-120,021 A, 1992 [C.A. 117: 251,362, 1992].
80. Yoneyama F, Yamada H, Satoh K, Taira N. Cardiac versus coronary dilator effects of SD-3211, a new non-dihydropyridine calcium antagonist, in isolated, blood-perfused dog heart. Cardiovasc Drug Ther 1990;4:1469-1476.